What is Kintor Pharmaceutical Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Kintor Pharmaceutical's Average Total Inventories for the quarter that ended in Dec. 2023 was HK$659.66 Mil. Kintor Pharmaceutical's Revenue for the
six
months ended in Dec. 2023 was HK$0.00 Mil.
Kintor Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Dec. 2023
stayed the same
from Jun. 2023 (0.00) to Jun. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Kintor Pharmaceutical's Days Inventory for the
six
months ended in Dec. 2023 was 2,606.42.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kintor Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.07.
Kintor Pharmaceutical Inventory-to-Revenue Historical Data
The historical data trend for Kintor Pharmaceutical's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintor Pharmaceutical's Inventory-to-Revenue
For the Biotechnology subindustry, Kintor Pharmaceutical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kintor Pharmaceutical's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Kintor Pharmaceutical's Days Inventory for the
six
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Kintor Pharmaceutical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintor Pharmaceutical (HKSE:09939) Business Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09939 has been successfully added to your 